To the Editor, In recent years, few studies have provided oncological outcomes with the potential to change clinical practice for patients with cervical cancer, leaving the standard model of combined chemoradiotherapy for locally-advanced disease largely unchanged. Over the past year, 2 phase-III clinical trials—KEYNOTE-A181 and INTERLACE2—have introduced new evidence with...